Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamsulosin for symptomatic dysuria in women with multiple sclerosis
2021-005025-25Phase 2Active
- Sponsor
- CHU Nîmes
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of tamsulosin in Micturition disorder and dysuria (2 arms), sponsored by CHU Nîmes. Primary endpoint: Change in IPSS score. Started Mar 2022; status: active.
02
Drugs
tamsulosin
03
Conditions
Micturition disorderdysuria
Beyond the preview
Go deeper on 2021-005025-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005025-25.